Justia Products Liability Opinion Summaries

Plaintiffs filed suit against Novartis in the Western District of Texas, then the case was transferred by the Judicial Panel on MDL to the Middle District of Tennessee. Plaintiffs' compliant alleged, inter alia, that Novartis failed to notify the public and physicians of the possibility of suffering osteonecrosis of the jaw until 2004 and failing to notify dental professionals until 2005. The MDL court granted partial summary judgment to Novartis and ruled that: (1) Texas law applied to plaintiffs' case, and (2) Tex. Civ. Prac. & Rem. Code 82.007(a) - which provides manufacturers a rebuttable presumption against liability for failing to warn - foreclosed plaintiffs' failure to warn claims. On remand, the district court granted summary judgment on plaintiffs' remaining claims. The court affirmed the denial of plaintiffs' Rule 56(d) and Rule 60(b) motions; the remand court properly applied the law of the case when it refused to reconsider the MDL court's rulings that section 82.007 applied to plaintiffs' failure to warn claims; and the remand court properly granted summary judgment on plaintiffs' warranty claims. Accordingly, the court affirmed the judgment of the district court. View "McKay, et al v. Novartis Pharmaceutical Corp." on Justia Law

In 2012, nineteen plaintiff families filed a single complaint alleging products liability and negligence claims against Defendants. In 2013, six plaintiff families filed a single complaint also alleging products liability and negligence claims against Defendants. The Chief Justice of the Supreme Court referred Plaintiffs as two civil actions to the Mass Litigation Panel. The Panel entered an order that transformed the two civil actions into twenty-five separate actions. Plaintiffs sought a writ of prohibition to preclude enforcement of the order on the grounds that the Panel did not have the authority to alter their status as two civil actions. The Supreme Court granted the writ, holding that the Panel did not have the authority to separate the cases. View "State ex rel. J.C. v. Judge Mazzone" on Justia Law

Plaintiff filed various products liability and general tort claims against the Brand Defendants - who initially developed and received FDA approval for metoclopramide - and Generic Defendants - who manufactured and sold the product that plaintiff used. Plaintiff alleged that as a result of his prolonged use of the drug metoclopramide, he developed tardive dyskinesia. On appeal, plaintiff challenged the district court's dismissal of his claims against the Brand Defendants and grant of summary judgment to the Generic Defendants. The court held that plaintiff's products liability claims against the Generic Defendants were preempted under the holdings and reasoning of PLIVA, Inc. v. Mensing and Mutual Pharmaceutical Co., Inc. v. Bartlett, and that plaintiff failed to adequately plead any parallel claims. The court also held that plaintiff's claims against the Brand Defendants failed because plaintiff did not use the Brand Defendants' products and because Texas did not recognize a duty to a consumer who uses a competitor's products. Accordingly, the court affirmed the district court's dismissal of plaintiff's claims against the Generic Defendants and grant of summary judgment to the Brand Defendants. View "Eckhardt, et al. v. Qualitest Pharmaceuticals, Inc., et al." on Justia Law

Plaintiff filed a negligence and strict products liability suit against Stryker, the manufacturer and seller of the pain pump that was inserted into her shoulder to mitigate her pain while recovering from surgery. Plaintiff's husband filed a claim for loss of consortium. The court concluded that Stryker could not have foreseen the potential for articular cartilage damage as the result of the surgical implementation of its pain pump on the medical community's knowledge in 2002; Stryker, as a matter of law, had no duty to protect or warn plaintiff of the harm that Stryker's pain pumps may inflict; and the FDA denials did not indicate to Stryker that use of its pain pumps in intra-articular spaces was unsafe or could result in foreseeable harm. Accordingly, the court affirmed the district court's grant of summary judgment to Stryker. View "Mack, et al. v. Stryker Corp., et al." on Justia Law

Tommie Patterson’s vehicle was struck from behind when he braked to avoid a car stalled in his lane of travel. He sued the owner of the stalled vehicle and subpoenaed her for trial, but she refused to appear. The Supreme Court concluded that the superior court should have issued a warrant or an order to show cause to compel the appearance of this party. In addition, the superior court instructed the jury on Patterson’s products liability claim against Ford Motor Company (manufacturer of Patterson's vehicle), but this claim was erroneously omitted from the special verdict form. Therefore, the Court reversed the superior court’s judgment and remanded this case for a new trial. View "Patterson v. Cox" on Justia Law

Plaintiffs Linda Two Two and Patricia Fodge filed a complaint against defendant that included claims for negligence and strict liability. Plaintiffs alleged that they had been injured in separate incidents in 2008 when an elevator in the building in which they worked dropped unexpectedly and stopped abruptly. In their negligence claim, plaintiffs alleged that defendant had negligently designed, installed, and maintained that elevator and that defendant's negligence was the direct and proximate cause of plaintiffs' injuries. In their strict liability claim, plaintiffs alleged that defendant had designed, installed, and constructed the elevator and that the elevator was defective and dangerous. Defendant sought summary judgment on both claims. The trial court granted defendant's motion for summary judgment on both claims. Upon review of the trial court record, the Supreme Court decided that the trial court erred in granting defendant's motion for summary judgment on plaintiffs' negligence claim, but did not err in granting defendant's motion for summary judgment on plaintiffs' strict liability claim. View "Two Two v. Fujitec America, Inc." on Justia Law

Seven years after Plyler installed a Whirlpool microwave oven and eight hours after using that oven, a houseguest woke him because of a fire in the microwave. Firefighters extinguished the fire. Plyler claims that he injured his elbow and knee while he ran into and out of his house and that he experienced post-traumatic stress disorder. At trial on negligent recall and strict liability claims, a fire department investigator could not identify a specific cause of the fire. Plyler blamed the fire on a product defect that had led Whirlpool to recall microwaves in 2001. Whirlpool’s Director of Global Product Safety testified that the ovens posed a fire hazard only if they contained splattered food. uncleaned for an extended time, and were running at the time of the fire. After Whirlpool discovered that 1.8 million microwaves contained the defect, it issued a recall through the Consumer Product Safety Commission, mailed notices to owners who had submitted a product registration card, and released news announcements. Although the average recall leads to repair or replacement of 10 to 15 percent of affected units, Whirlpool repaired 75 percent of the recalled microwave. Plyler stated that he kept his microwave clean; that he never received notice; that he paid for it with a credit card; and that Whirlpool should have been able to contact him. The jury found in favor of Whirlpool. The Seventh Circuit affirmed, rejecting challenges to rulings that limited Plyler’s testimony to his observations and that allowed questions about the relationship between the fire and his divorce.View "Plyler v. Whirlpool Corp." on Justia Law

In 1995 the FDA approved Fosamax® to treat or prevent osteoporosis and Paget’s Disease. Teva developed alendronate sodium, a generic form of the branded drug, and obtained FDA approval on its abbreviated new drug application in 2008. Other generic manufacturers subsequently obtained approval for formulations. The drugs act by inhibiting bone resorption or absorption and suppressing bone turnover; they also inhibit primary mineralization, which is involved in the formation of new bone. Meanwhile, secondary mineralization of existing bone continues, which increases the bone’s mineral content and results in higher bone mineral density. According to the plaintiffs, higher bone mineral density does not necessarily correspond with reduction of fracture risk but can make bone highly mineralized, homogenous, brittle, and more susceptible to fracture. According to some studies, the effects of alendronate sodium linger, with one study reporting that bone turnover may be inhibited by 50% five years after discontinuing treatment. The district court granted judgment on the pleadings in favor of the generic manufacturer defendants finding that state-law strict liability claims were pre-empted by federal law. The Seventh Circuit affirmed. Manufacturers have no control over the design or labeling of generic drugs; the plaintiffs failed to identify anything the generic defendants could do to reconcile their conflicting duties under state and federal law. View "In re: Fosmax (Alendronate Sodium)" on Justia Law

In the late 1990s, people who had taken the prescription diet-drug combination Fen-Phen began suing Wyeth, claiming that the drugs caused valvular heart disease. A 2000 settlement included creation of the Fen-Phen Settlement Trust to compensate class members who had sustained heart damage. Claims required medical evidence. Attorneys who represented certain claimants retained Tai, a board-certified Level 2-qualified cardiologist, to read tests and prepare reports. Tai read 12,000 tests and asserted that he was owed $2 million dollars for his services. Tai later acknowledged that in about 10% of the cases, he dictated reports consistent with the technicians’ reports despite knowing that the measurements were wrong, and that he had his technician and office manager review about 1,000 of the tests because he did not have enough time to do the work. A review of the forms Tai submitted found that, in a substantial number of cases, the measurements were clearly incorrect and were actually inconsistent with a human adult heart. Tai was convicted of mail and wire fraud, 18 U.S.C. 1341 and 1343, was sentenced to 72 months’ imprisonment, and was ordered to pay restitution of $4,579,663 and a fine of $15,000. The Third Circuit rejected arguments that the court erred by implicitly shifting the burden of proof in its “willful blindness” jury instruction and applying upward adjustments under the advisory Sentencing Guidelines for abuse of a position of trust and use of a special skill, but remanded for factual findings concerning whether Tai supervised a criminally culpable subordinate, as required for an aggravated role enhancement. View "United States v. Tai" on Justia Law

Robert Reeves, an employee of Illinois Central Railroad, sued Mississippi Valley Silica, Inc. for lung injuries that allegedly were caused by his inhalation of silica while employed with Illinois Central. The case was dismissed without prejudice in 2006, and this suit was filed against thirty-two named defendants in 2007. Robert Reeves died in 2010, before the litigation was concluded, and the case then was pursued by his wrongful death beneficiaries. After trial in May 2012 against the sole remaining defendant, Valley, the jury found economic damages in the amount of $149,464.40 and noneconomic damages of $1.5 million, with Valley 15% at fault. The jury also awarded punitive damages of $50,000, and the trial court awarded attorney fees of $257,701.50. Although Valley was found only 15% at fault, the trial court determined that the law in place in 2002, when the original complaint was filed, should have applied. Accordingly, the statutory caps on punitive and noneconomic damages enacted in 2004 were inapplicable and Valley was jointly and severally liable for 50% of the judgment. Ultimately, the court determined that Valley owed the Reeves beneficiaries $824,732.20, plus $50,000 in punitive damages, and $257,701.50 in attorney fees, for a total of $1,132,433.70. Valley appealed. Upon review of the matter, the Supreme Court concluded that plaintiff failed to present sufficient evidence to identify Valley’s sand as the proximate cause of Robert Reeves’s injuries as a matter of law. Therefore, the Court reversed the trial court and rendered judgment in favor of Mississippi Valley Silica. View "Mississippi Valley Silica Company, Inc. v. Reeves" on Justia Law